Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

作者：Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, Jacques J. Genest, Antonio M. Gotto, John J.P. Kastelein, Wolfgang Köenig, Peter Libby, Alberto J. Lorenzatti, Jean G. MacFadyen, Børge Grønne Nordestgaard, James Banks Shepherd, James T. Willerson, Robert J. Glynn · 发表于：Obstetrical & Gynecological Survey · 年份：2009 · DOI：10.1097/01.ogx.0000344393.60303.0a · 被引用次数：3655 · 研究领域：Lipoproteins and Cardiovascular Health、Cardiac Valve Diseases and Treatments

Previous studies have shown that statin therapy reduces high-sensitivity C-reactive protein levels as well as cholesterol, but no prospective trials have directly addressed the issue of whether elevated levels of high-sensitivity C-reactive protein are beneficial for apparently healthy persons with levels of LDL cholesterol below current thresholds for treatment. This randomized, double-blind, placebo-controlled, multicenter trial study was part of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Study. The present study evaluated the effects of rosuvastatin, 20 mg daily, or placebo in 17,802 apparently healthy men and women with LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher. Following randomization, study subjects were followed for the occurrence of the combined primary end point: myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. The trial was terminated after a median follow-up of 1.9 years (maximum, 5.0). As compared with the placebo at the 12-month visit, rosuvastatin reduced LDL cholesterol levels by 50%, high-sensitivity C-reactive protein levels by 37%, and triglyceride levels by 17% (P < .001 for all three comparisons). For rosuvastatin and placebo, the rates of the primary end point were 0.77 and 1.36 per 100 person-...